冠心病药物、经皮与外科干预结局的性别差异
本综述总结冠心病患者在药物治疗、经皮冠状动脉介入和冠状动脉旁路移植术后结局的性别差异证据。文中指出女性在抗血小板治疗期间残留血小板反应性更高、经皮血运重建后不良心血管结局更多、冠脉搭桥术后手术及长期死亡率更高。尽管性别特异性结局决定因素日益受重视,女性在临床研究中的代表性仍偏低,指南一般未提供性别特异性管理策略。
要点
- 女性抗血小板治疗期间残留血小板反应性高于男性。
- 女性经皮冠脉血运重建后不良心血管结局发生率更高。
- 女性冠脉搭桥术后手术死亡率和长期死亡率均高于男性。
核心结论
- 女性在冠心病药物、经皮及外科干预后的结局较男性更差,但指南一般未提供性别特异性管理策略。
研究设计与样本
- 综述类文章,汇总冠心病患者药物治疗、经皮冠状动脉介入与冠状动脉旁路移植术后结局性别差异的现有证据。
主要发现
- 女性在抗血小板药物治疗期间残留血小板反应性水平高于男性。
- 女性经皮冠状动脉血运重建后不良心血管结局发生率高于男性。
- 女性冠状动脉旁路移植术后手术死亡率和长期死亡率高于男性。
- 女性在临床研究中的代表性仍然偏低。
临床怎么用
- 临床应关注女性冠心病患者在抗血小板治疗、经皮血运重建及搭桥术后的更高风险。
局限性
- 女性在临床研究中代表性低,性别特异性管理策略一般未纳入指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biological and sociocultural differences between men and women are complex and likely account for most of the variations in the epidemiology and treatment outcomes of coronary artery disease (CAD) between the 2 sexes. Worse outcomes in women have been described following both conservative and invasive treatments of CAD. For example, increased levels of residual platelet reactivity during treatment with antiplatelet drugs, higher rates of adverse cardiovascular outcomes following percutaneous coronary revascularization, and higher operative and long-term mortality after coronary bypass surgery have been reported in women compared with in men. Despite the growing recognition of sex-specific determinants of outcomes, representation of women in clinical studies remains low and sex-specific management strategies are generally not provided in guidelines. This review summarizes the current evidence on sex-related differences in patients with CAD, focusing on the differential outcomes following medical therapy, percutaneous coronary interventions, and coronary artery bypass surgery.
引用
- Gaudino M, Di Franco A, Cao D, et al. Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease: JACC Focus Seminar 3/7. J Am Coll Cardiol. 2022. PMID: 35393023. doi:10.1016/j.jacc.2021.07.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。